Sofosbuvir impurity K - 10mM in DMSO , CAS No.1496552-51-2

CAS: 1496552-51-2 Cat. No.: S654747 Fórmula: C22H29ClN3O9P Peso molecular: 545.91 PubChem CID: 123474062
Disponible para pedir
CALIDAD & PUREZA 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
Talla
Alemania (EU)
USA*
Precio
Cantidad
1ml
S654747-1ml
Fabricado bajo pedido · 8–12 semanas
7.295,86€
Enter a quantity for the sizes you want to add.

Descripción general

Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

IC50& Target:HCV

Especificaciones

Especificaciones y pureza
10mM in DMSO
Mecanismos bioquímicos y fisiológicos
Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
Condiciones de almacenamiento de almacenamiento
Store at -80°C
Enviado en
Dry ice packs + Cold packs
Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.
Nombres e identificadores
PubChem CID
123474062
Peso molecular
545.91

Datos avanzados

Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluciones
Reseñas

Reseñas de cliente

Application Protocols

Item-specific protocols

  • None provided for this item; refer to CoA/Spec Sheet.

General protocols for impurity standards (analytical use)

  • Stock preparation: Equilibrate vial to room temperature in a desiccator. Briefly centrifuge. Weigh accurately in a dry environment. Dissolve in dry DMSO or ACN to a convenient concentration (e.g., 1–10 mg/mL). Record exact concentration by mass.
  • Working solutions: Dilute stocks with mobile phase or diluent to the desired µg/mL or µM range immediately before analysis. Prepare fresh daily unless stability has been established.
  • Calibration: Prepare multi-level calibration standards (e.g., 5–8 points) spanning expected impurity levels. Use internal standards when possible.
  • System suitability: Co-inject with sofosbuvir matrix to verify resolution, tailing, and response factors. Confirm identity by MS where available.
  • Storage of solutions: Keep chilled during sequences; discard after use unless solution stability is documented under the specific conditions.

Documentation

  • Capture chromatograms, spectra, and all preparation calculations in your analytical notebook/LIMS for traceability.
Biological Roles

Applicability

  • As an API-related impurity reference standard, Sofosbuvir impurity K is not intended for biological assays or therapeutic use.

General/literature context

  • Sofosbuvir is a nucleotide prodrug; its impurities may derive from process intermediates, isomers, degradants, or over-/under-protected analogs. Such impurities are monitored to ensure quality and safety of the corresponding API.
  • While some related substances may retain partial structural motifs of the parent, impurity standards should not be assumed to possess any meaningful biological activity. No biological role is ascribed to impurity K in this listing.

Laboratory considerations

  • If used as a system suitability spike in bioanalytical LC–MS assays, ensure that matrix effects (protein binding, ion suppression) are assessed empirically. Validate recovery and stability in the chosen biological matrix if such use is contemplated, recognizing this product is for research use only.

Item-specific data

  • No biochemical pathway involvement, receptor binding, or enzymatic interactions are specified for this item. Refer to CoA/Spec Sheet if any additional characterization is provided.
Buffer Applications

Not typically applicable.

  • Sofosbuvir impurity K is not a buffering agent and does not form a defined conjugate acid/base pair for pH control.

General analytical context

  • In chromatographic analyses of sofosbuvir and related substances, volatile buffers (e.g., 5–20 mM ammonium acetate/formate, with or without 0.05–0.1% formic acid) are commonly used to tune ionization and retention. Selection depends on detector (UV vs MS) and column chemistry.

Item-specific note

  • No buffer capacity, pKa, or formulation buffer recommendations are provided for this item; refer to your analytical method requirements.
Green Alternatives

Context

  • As a reference standard used in analytical workflows, the primary environmental impact stems from solvent consumption in sample prep and chromatography rather than from the impurity itself.

Greener choices (general guidance)

  • Replace acetonitrile with ethanol or methanol where chromatographic selectivity allows; consider water-rich eluents with volatile buffers (ammonium formate/acetate) to reduce organic usage.
  • Superficially porous particle (SPP) columns or shorter sub-2 µm columns can reduce run time and solvent use without compromising resolution. Temperature optimization can further lower solvent consumption.
  • Explore ethanol-based sample diluents for UV-only detection when MS compatibility is not required.

Trade-offs

  • Methanol and ethanol are greener than ACN but increase viscosity and backpressure; they may alter selectivity in ways that require re-optimization.
  • Highly polar impurities may demand DMSO stocks; while not particularly green, DMSO quantities are small when preparing micromolar standards.

Mini-comparison (general)

  • ACN/water (0.1% FA): sharp peaks, low viscosity, MS-friendly, higher environmental burden.
  • MeOH/water (0.1% FA): greener, higher backpressure, different selectivity that can aid separation of isomers.
  • EtOH/water (volatile buffer): greener, may require elevated temperature and robust columns.

Item-specific note

  • No item-specific solvent or method restrictions are provided; optimization should be driven by analytical performance and sustainability goals.
Pharmaceutical Uses

Applicability

  • Not a therapeutic product. For research use only.

General/industry role

  • API impurity reference standards are used in GMP and research settings for: identification and quantitation of specified and unspecified impurities; method development and validation (specificity, linearity, accuracy); stability-indicating method qualification; release and stability testing of drug substance and drug product.
  • Such standards support ICH Q3A/Q3B compliance by enabling robust impurity profiling and reporting. They may also be used to define relative response factors in LC–UV methods or to calibrate LC–MS quantitation.

Regulatory notes (general)

  • When employed in GMP environments, ensure traceable documentation: CoA with assay and uncertainty, reference to characterization data, lot number, retest/expiry, storage conditions, and chain-of-custody.

Item-specific information

  • No pharmacopeial monograph status, reference standard designation (e.g., USP/EP CRS), or certified reference material status is specified for this item; refer to CoA/Spec Sheet for grade and suitability statements.
Physical Properties

Item-specific facts (from Product Data)

  • Physical state/appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point: Not specified for this item; refer to CoA/Spec Sheet.
  • Boiling point: Not applicable/Not typically reported for such solids; refer to CoA/Spec Sheet.
  • Density: Not specified for this item; refer to CoA/Spec Sheet.
  • Solubility: Not specified for this item; refer to CoA/Spec Sheet.
  • LogP, pKa, refractive index: Not specified for this item; refer to CoA/Spec Sheet.

General/literature context

  • Sofosbuvir-related impurities are commonly obtained as solids or semi-solids. Many exhibit good solubility in DMSO and polar organic eluents used in LC (e.g., acetonitrile, methanol) and limited solubility in nonpolar hydrocarbons. The exact solubility profile of impurity K must be verified against its structure.
  • UV characteristics for nucleoside-like species often show absorbance in the 200–320 nm region; specific maxima and extinction coefficients depend on the base and substituents and should be determined experimentally.

Practical notes (general guidance)

  • Prepare small aliquots in dry, oxygen-limited conditions if the impurity bears hydrolytically or oxidatively labile groups (e.g., phosphoramidates, esters). Use anhydrous solvents and analyze promptly by LC-UV or LC–MS to confirm integrity.
  • Record appearance and any hygroscopic behavior upon first opening to guide future handling. For method development, screen DMSO, acetonitrile, methanol, and water (with formic acid or ammonium salts) to establish a robust diluent and chromatographic system.
Quality and Grades

Item-specific facts (from Product Data)

  • Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

Context and expectations for impurity reference standards (general)

  • Reference impurities linked to APIs are typically supplied with a detailed Certificate of Analysis (CoA) including assay/purity (often by qNMR, HPLC area%), water/volatile content, residual solvent screening, and structural confirmation (1H/13C NMR, HRMS, sometimes 31P NMR for phosphoramidates) along with chromatographic trace.
  • For LC method development, “HPLC reference” or “certified reference material (CRM)” designations imply tight control of compositional purity and uncertainty; absence of such designation means laboratories should independently verify suitability for quantitation.
  • Stabilizers: If present (e.g., small amounts of acid/base or antioxidants to suppress degradation), these will be declared on the CoA. None are specified here for this item.

Best practices

  • Upon receipt, verify identity by LC–MS and compare retention time with vendor trace. If quantitation is intended, consider bracketing with an internal standard and perform independent purity assessment (qNMR or mass balance).
  • Document traceability: lot numbers, expiry/retest dates, storage history, and aliquoting records are essential for GMP/GLP environments.
Reaction and Applications

Applicability

  • This material is not primarily used as a reagent but as a reference standard for analytical control of sofosbuvir manufacturing and stability. No item-specific reaction data are provided.

Applications (general/literature)

  • Method development: Establishing specificity and resolution in stability-indicating HPLC/UPLC methods by spiking known levels of impurity K into sofosbuvir API or formulation matrices.
  • System suitability/identification: Verifying retention time and mass spectral fingerprint in LC–MS workflows; supporting forced-degradation studies (acid/base hydrolysis, oxidation, thermolysis) to confirm peak assignments.
  • Calibration/quantitation: Creating external calibration curves for impurity profiling; using qNMR to assign mass fraction purity to support primary-standard use.
  • Structural confirmation: Comparing NMR and HRMS data with vendor-provided spectra to validate identity in regulatory submissions.

Practical tips

  • Prepare fresh working solutions immediately prior to use to minimize hydrolysis/oxidation if the structure contains labile functions. Keep vials cold and protected from light during sequence runs.
  • Use bracketed injections and internal standards to correct for carryover and instrument drift. For LC–MS, assess adduct patterns (e.g., [M+H]+, [M+Na]+) and in-source fragmentation to improve specificity.

Item-specific reactions

  • Not applicable; no synthetic or transformation uses are specified for this item.
Reaction Conditions

Not typically applicable as a reagent.

Analytical conditions (general guidance, literature-based)

  • LC–UV/LC–MS: Reversed-phase C18 or polar-embedded columns; mobile phase A: water with 0.05–0.1% formic acid or 5–20 mM ammonium formate/acetate; mobile phase B: acetonitrile or methanol. Gradient 5–60% B over 5–20 min is a common starting point. Column temperature 30–45°C; flow 0.2–0.6 mL/min (UHPLC) or 0.8–1.2 mL/min (HPLC). Adjust to resolve impurity K from neighboring peaks.
  • Detection: UV in the 200–320 nm range depending on chromophore; MS in positive/negative ESI depending on acid/base character of the impurity. Optimize source conditions to minimize in-source fragmentation.
  • Sample prep: Prepare micromolar solutions in DMSO, ACN, or MeOH; dilute into initial mobile phase for injection. Filter through 0.2 µm PTFE/nylon if compatible, avoiding adsorptive losses.

Forced degradation mapping (if applicable)

  • To confirm peak assignment during method validation, apply mild acid/base hydrolysis, oxidative stress (e.g., H2O2 traces), heat, and light per ICH Q1A guidelines to the parent API and track formation of impurity K. Exercise caution; do not subject the impurity standard itself to unnecessary stress.

Item-specific parameters

  • None are specified for this item; refer to your validated method or CoA guidance.
Safety and Handling

Item-specific facts (from Product Data)

  • GHS classification, pictograms, signal word, H-statements: Not specified for this item; refer to SDS.
  • Storage conditions: Store at -80°C.
  • Shipping: Dry ice packs + Cold packs.

General safety guidance (not a substitute for the SDS)

  • Handle reference impurities as potentially harmful organic solids. Avoid inhalation of dust/aerosols and skin/eye contact. Use appropriate PPE: lab coat, safety glasses, and suitable gloves (e.g., disposable nitrile). Work in a fume hood during weighing and solution preparation.
  • Potential incompatibilities: If the impurity contains hydrolyzable groups (e.g., phosphoramidate, ester), avoid prolonged exposure to moisture, strong acids/bases, and elevated temperatures. Protect from light if chromophore photosensitivity is suspected.
  • First aid (overview): In case of skin contact, wash with soap and water. For eye exposure, rinse cautiously with water for several minutes; remove contact lenses if present and easy to do. If inhaled, move to fresh air. If swallowed, rinse mouth; do not induce vomiting. Seek medical attention in all cases of significant exposure.
  • Waste: Collect solutions and contaminated materials as halogen-free organic waste unless structure indicates otherwise. Follow institutional hazardous waste procedures.

Always consult the product SDS for authoritative hazard classification, exposure limits, and emergency measures.

Solvent Selection

Applicability

  • As a small-molecule impurity/reference standard, solvent choice is primarily for dissolution and analytical chromatography rather than synthetic transformations.

General guidance (literature/practice)

  • Primary diluents: DMSO (excellent solvating power for polar and moderately lipophilic impurities), acetonitrile (ACN), and methanol (MeOH). Water may be used for aqueous injections if the impurity is sufficiently polar.
  • LC mobile phases: Water with 0.05–0.1% formic acid or 5–20 mM ammonium formate/acetate paired with ACN or MeOH is common for LC–UV/MS assays of sofosbuvir-related substances. Select additives compatible with the detector.
  • Avoid strong basic diluents if the impurity contains base-labile groups (e.g., phosphoramidate). For acid-labile functionalities, keep pH near neutral during dissolution.

Selection considerations

  • Choose DMSO for stock solutions aimed at long-term freezer storage and accurate microliter dosing.
  • Prefer ACN over MeOH for LC–MS when you need lower viscosity and sharper peaks; choose MeOH to modulate selectivity for closely eluting isomers.
  • For preparative isolation, mixed solvents (e.g., ACN/water) help manage precipitation during fraction collection.

Item-specific note

  • Solubility and stability of Sofosbuvir impurity K in each solvent are Not specified for this item; refer to CoA/Spec Sheet. Confirm experimentally prior to scale-up or quantitative use.
Storage and Reconstitution

Item-specific facts (from Product Data)

  • Storage: Store at -80°C.
  • Shipping: Dry ice packs + Cold packs.

General handling guidance

  • Upon receipt, keep the container at -80°C until use. Allow the sealed vial to equilibrate to room temperature in a desiccator before opening to prevent moisture condensation.
  • If material is hygroscopic or hydrolysis-prone (common for certain sofosbuvir-related species), work quickly in a low-humidity environment. Purge vial headspace with dry inert gas before re-closing.
  • Aliquoting: Immediately subdivide into single-use aliquots in amber microvials to minimize freeze–thaw cycles. Record aliquot masses and concentrations.

Reconstitution (general)

  • Solvent: Dry DMSO, acetonitrile, or methanol are typical initial solvents for preparing concentrated stocks. The exact solvent compatibility for Sofosbuvir impurity K is Not specified for this item; refer to CoA/Spec Sheet and confirm experimentally at small scale.
  • Concentration: Choose a stock level that avoids repeated thawing and ensures accurate pipetting (e.g., 1–10 mg/mL). Mix gently until fully dissolved; avoid prolonged sonication if hydrolysis-sensitive.

Stability considerations

  • Store solutions at ≤-20°C (short-term) or -80°C (long-term) in tightly sealed, moisture-protected vials. Protect from light if chromophore sensitivity is suspected. Reassess purity by LC prior to critical use if a solution has been stored for more than 24–48 hours.

For authoritative stability limits and retest dates, consult the product CoA.

Structure and Identity

Item-specific facts (from Product Data)

  • Product name: Sofosbuvir impurity K (SKU: S654747)
  • CAS: 1496552-51-2
  • PubChem CID: 123474062
  • InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature context

  • “Sofosbuvir impurity K” denotes a defined related substance associated with the synthesis, degradation, or process stream of the nucleotide prodrug sofosbuvir. Different impurity letters (A, B, C, …) are used by compendia/manufacturers to track distinct structures.
  • Without the provided SMILES/InChIKey, specific functional groups and stereochemical features for impurity K cannot be asserted here. Many sofosbuvir-related impurities feature nucleoside cores, phosphoramidate/phosphate motifs, or modified aromatic/alkoxy substituents, but the exact identity of impurity K should be confirmed from the CoA/SDS or primary reference standard documentation.

How to describe the 2D structure (guidance)

  • If structure is provided in CoA: Note ring systems (e.g., ribosyl/furanose ring, heteroaryl base), presence/absence of phosphoramidate or phosphate, and any isopropoxy/aryloxy substituents. Identify stereocenters on the sugar and phosphorus if applicable.
  • Provide canonical and isomeric SMILES and InChIKey in your lab records to ensure unambiguous traceability across analytical platforms.
Synthetic Utility

Applicability

  • This product is a reference impurity and is not typically employed as a reagent, building block, or intermediate in synthesis.

General context

  • In process chemistry, isolated impurities can inform retrosynthetic analysis and mechanism elucidation (e.g., pathways of hydrolysis of phosphoramidate groups, epimerization at phosphorus or sugar centers, or side reactions during coupling/protection). Authentic samples like impurity K enable benchmarking against hypothesized byproducts.
  • Comparative NMR and LC–MS fragmentation of impurity K versus proposed structures can validate or refute mechanistic proposals, guiding process optimization and control strategies.

Practical uses in the lab

  • Spike authentic impurity K into batch samples to evaluate purge factors across unit operations.
  • Use as a co-injection marker to optimize chromatographic resolution between critical pairs.

Item-specific note

  • No reactivity data or transformation protocols are provided for this item; if structural information is available in the CoA, reactivity inferences should be derived from the declared functional groups and tested at micro-scale only.
Target Specificity

Not applicable.

  • This product is a small-molecule impurity reference standard, not a biological targeting reagent (e.g., antibody, inhibitor with defined target claims). No antigen, epitope, species reactivity, clone, or isotype information applies.

Preguntas frecuentes

How should this product be stored?
Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 1496552-51-2, the molecular formula is C22H29ClN3O9P, and the molecular weight is 545.91 g/mol.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

¿Quieres que te enviemos un mensaje cuando tengamos descuentos disponibles?

Recordármelo más tarde

¡Gracias! Por favor, revisa tu bandeja de entrada de correo electrónico para confirmar.

¡Vaya! Las notificaciones están desactivadas.